GYRE - GYRE THERAPEUTICS, INC.
7.94
-0.160 -2.015%
Share volume: 50,625
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.17%
PREVIOUS CLOSE
CHG
CHG%
$8.10
-0.16
-0.02%
Summary score
41%
Profitability
46%
Dept financing
28%
Liquidity
75%
Performance
30%
Sector
Manufacturing
Industry
Pharmaceutical Products/Pharmaceutical Preparations
Long-term ratios 31-Dec-2021 - 31-Dec-2025
The data are presented for the financials results of the quarters of the last 4 years.
Return on equity
-78.37%
Return on assets
-6.17%
Return on sales
-172.31%
Return on invested capital
-219.86%
Total debt ratio
44.25%
Debt ratio change over timeo
-1.69%
Current Ratio
5.42%
Quick Ratio
5.19%
Cash Position Ratio
3.36%
Short-term ratios 31-Dec-2024 - 31-Dec-2025
The data are presented for the financials results of the quarters of the last year.
Return on equity
0%
Return on assets
2.18%
Return on sales
10.35%
Return on invested capital
0%
Total debt ratio
39.86%
Debt ratio change over timeo
0%
Current Ratio
5.2%
Quick Ratio
4.69%
Cash Position Ratio
1.88%
Last quarter ratios 31-Dec-2025
The data are presented for the financials results of the last quarter.
Return on equity
0%
Return on assets
-1.09%
Return on sales
0.32%
Return on invested capital
0%
Total debt ratio
36.18%
Debt ratio change over time
0%
Current Ratio
5.6%
Quick Ratio
5.04%
Cash Position Ratio
2.03%
Performance ratios (change over 4 years) 31-Dec-2021 - 31-Dec-2025
The data are presented for the change financials results of the quarter of the last 4 years.
Return on equity
-6.47%
Return on assets
-88.71%
Return on sales
-423.88%
Return on invested capital
-92.59%
Total debt ratio
-168.6%
Debt ratio change over time
-1.69%
Current Ratio
-2.91%
Quick Ratio
-2.85%
Cash Position Ratio
-2.34%
Compare in sector
The following table compares the individual analyzes for the other top 3 stocks within the same industry.
| Long-term ratios | GYRE | LLY | JNJ | ABBV |
|---|---|---|---|---|
| Return on equity | -78.37% | 12.23% | 10.41% | 0% |
| Return on assets | -6.17% | 4.74% | 3.19% | 1.73% |
| Return on sales | -172.31% | 30.88% | 25.28% | 24.06% |
| Return on invested capital | -219.86% | 8.04% | 10.95% | 0% |
| Profitability | 0% | 93% | 84% | 29% |
| Total debt ratio | 44.25% | 80.37% | 59.38% | 94.09% |
| Debt ratio change over time | -1.69% | -20.57% | -85.61% | 17.33% |
| Dept financing | 12% | 21% | 16% | 50% |
| Current Ratio | 5.2% | 1.44% | 1.09% | 0.72% |
| Quick Ratio | 4.69% | 1.12% | 0.84% | 0.6% |
| Cash Position Ratio | 1.88% | 0.16% | 0.44% | 0.14% |
| Liquididy | 75% | 11% | 14% | 9% |
| Short-term ratios | GYRE | LLY | JNJ | ABBV |
|---|---|---|---|---|
| Return on equity | 0% | 0% | 0% | 0% |
| Return on assets | 2.18% | 6.06% | 4.18% | 1.7% |
| Return on sales | 10.35% | 39.61% | 26.91% | 24.78% |
| Return on invested capital | 0% | 0% | 0% | 0% |
| Profitability | 66% | 50% | 34% | 23% |
| Total debt ratio | 39.86% | 80% | 59.26% | 100.88% |
| Debt ratio change over time | 0% | 0% | 0% | 0% |
| Dept financing | 35% | 20% | 15% | 25% |
| Current Ratio | 5.2% | 1.44% | 1.09% | 0.72% |
| Quick Ratio | 4.69% | 1.12% | 0.84% | 0.6% |
| Cash Position Ratio | 1.88% | 0.16% | 0.44% | 0.14% |
| Liquididy | 75% | 15% | 16% | 9% |